Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar;27(3):604-614.
doi: 10.1007/s11605-022-05559-8. Epub 2022 Dec 22.

Yttrium-90 Radioembolization: Current Indications and Outcomes

Ahmad Hamad  1 , Hassan Aziz  2 , Ihab R Kamel  3 , Dayssy Alexandra Diaz  4 , Timothy M Pawlik  5   6
Affiliations
Review

Yttrium-90 Radioembolization: Current Indications and Outcomes

Ahmad Hamad et al. J Gastrointest Surg. 2023 Mar.

Abstract

Background: Radioembolization (RE) with 90Yttrium (Y90) has generally been used to treat patients with advanced disease. Recent data suggest, however, that RE is also safe and feasible to treat patients with early or intermediate stage disease. We herein review the current evidence regarding the use of RE with Y90 for patients with HCC.

Methods: A comprehensive review of the literature was performed using MEDLINE/PubMed and Web of Science databases with a search end date of August 1, 2022.

Results: Patients with HCC are often treated according to the BCLC staging system. Among patients with early-stage HCC (BCLC A), intermediate-stage HCC (BCLC B), and advanced-stage HCC (BCLC C), RE with Y90 has demonstrated promising results with comparable overall survival, time to disease progression, and radiological response compared with other standard of care treatment modalities. Moreover, Y90 RE can be used as a downstaging treatment modality for patients with advanced HCC who have a disease burden that is initially outside LT criteria. Radiation lobectomy (RL) has been described as a treatment modality with the intent of treating the ipsilateral liver that harbors the HCC, while also causing compensatory hypertrophy of the future liver remnant (FLR).

Conclusion: While initially considered as a palliative option for HCC patients, Y90 RE has emerged as an important part of the multi-modality care of patients with HCC across a wide spectrum of clinical indications.

Keywords: Hepatocellular carcinoma; Radioembolization; Yttrium-90.

PubMed Disclaimer

References

    1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol Off J Am Soc Clin Oncol 2009;27:1485–91 [PMID: 19224838. https://doi.org/10.1200/JCO.2008.20.7753 ] - DOI
    1. Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology 2019;156:477-491.e1 [PMID: 30367835. https://doi.org/10.1053/j.gastro.2018.08.065 ] - DOI - PubMed
    1. Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol 2016;25:74–85 [PMID: 27312032. https://doi.org/10.1016/j.suronc.2016.03.002 ] - DOI - PubMed
    1. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76:681–93 [PMID: 34801630. https://doi.org/10.1016/j.jhep.2021.11.018 ] - DOI - PubMed
    1. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–38 [PMID: 10518312. https://doi.org/10.1055/s-2007-1007122 ] - DOI - PubMed

LinkOut - more resources